Podcasts about pulmonary medicine

Guest: Yana Zemkova, MD How often are ICU patients conscious during intubation despite paralysis? Hear from Dr. Yana Zemkova as she discusses new findings on the incidence of awareness with paralysis and the urgent need for improved monitoring in critical care. Dr. Zemkova is Clinical Assistant Professor of Internal Medicine specializing in Pulmonary, Critical Care and Occupational Medicine at the University of Iowa, and she spoke about this topic at the 2025 CHEST Annual Meeting.

Guest: Yana Zemkova, MD How often are ICU patients conscious during intubation despite paralysis? Hear from Dr. Yana Zemkova as she discusses new findings on the incidence of awareness with paralysis and the urgent need for improved monitoring in critical care. Dr. Zemkova is Clinical Assistant Professor of Internal Medicine specializing in Pulmonary, Critical Care and Occupational Medicine at the University of Iowa, and she spoke about this topic at the 2025 CHEST Annual Meeting.

Guest: Sujith Cherian MD, FCCP, DAABIP Obesity impacts how the lungs function in a variety of ways, and understanding these impacts is essential for interpreting pulmonary function tests, identifying restrictive or obstructive patterns, and managing ventilation. Learn more with Dr. Sujith Cherian, who's an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School and the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston. He also spoke about this topic at the 2025 CHEST Annual Meeting.

Guest: Sujith Cherian MD, FCCP, DAABIP Obesity impacts how the lungs function in a variety of ways, and understanding these impacts is essential for interpreting pulmonary function tests, identifying restrictive or obstructive patterns, and managing ventilation. Learn more with Dr. Sujith Cherian, who's an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School and the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston. He also spoke about this topic at the 2025 CHEST Annual Meeting.

Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.

Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.

As medicine shifts toward race-neutral lung function interpretation, new challenges emerge in ensuring equitable access to care. Dr. Ajay Sheshadri explores how race-neutral spirometry may impact patient selection for lung resection surgery and hematopoietic cell transplantation. Dr. Sheshadri is an Associate Professor in the Department of Pulmonary Medicine at the University of Texas MD Anderson Cancer Center.

Race-based spirometry adjustments have long influenced pulmonary risk assessments, often underestimating disease severity in Black patients. Hear from Dr. Ajay Sheshadri as he examines the historical misuse of race in lung function testing, explores race-neutral modeling in surgical risk prediction, and highlights the need for data-driven, continuous risk assessment tools in caring for patients with non-small cell lung cancer. Dr. Sheshadri is an Associate Professor in the Department of Pulmonary Medicine at the University of Texas MD Anderson Cancer Center.

Host: Ryan Quigley In a 2025 study investigating salivary metabolites as potential biomarkers in cystic fibrosis, researchers identified distinct metabolic patterns linked with key complications as well as correlations with lung function. In this AudioAbstract, Ryan Quigley discusses how a simple saliva sample could provide clinicians with an accessible, non-invasive tool to stratify patients, monitor therapies, and advance personalized care in cystic fibrosis. This topic was also discussed at the 2025 CHEST Annual Meeting.

Host: Ryan Quigley In a 2025 study investigating salivary metabolites as potential biomarkers in cystic fibrosis, researchers identified distinct metabolic patterns linked with key complications as well as correlations with lung function. In this AudioAbstract, Ryan Quigley discusses how a simple saliva sample could provide clinicians with an accessible, non-invasive tool to stratify patients, monitor therapies, and advance personalized care in cystic fibrosis. This topic was also discussed at the 2025 CHEST Annual Meeting.

A 2025 study in Chest evaluated PREDICT, a precision medicine program at a large academic-community practice, designed to streamline testing and expand access to personalized treatment for non-small cell lung cancer (NSCLC). Hear from ReachMD's Ryan Quigley as he shares the key impacts of this approach and implications for care delivery.

Host: Diego Maselli, MD, FCCP Guest: Stephanie Christenson, MD Despite triple inhaled therapy, many patients with chronic obstructive pulmonary disease (COPD) continue to experience frequent and severe exacerbations, leading to hospitalizations, symptom burden, and higher mortality risk. In this expert-led discussion, Drs. Diego Maselli and Stephanie Christenson personalized treatment approaches and the role of biologics in advanced COPD care. Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health San Antonio, and Dr. Christenson is an Associate Professor in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine and an attending physician on the Pulmonary Consult Service and in the Pulmonary Clinic at the University of California in San Francisco. This program is produced in partnership with the American College of Chest Physicians and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.

Moderator: Amit Bobby Mahajan, MD, FCCP, DAABIP Guest: Jonathan Kurman, MD Guest: Surya Bhatt, MD New strategies like advanced pharmacologic agents and bronchoscopic lung volume reduction are redefining COPD and emphysema management. Dr. Bobby Mahajan sits down with Drs. Surya Bhatt and Jonathan Kurman to highlight emerging strategies for identifying ideal candidates, optimizing patient selection, and combining therapies to reduce dyspnea and improve outcomes. Dr. Mahajan is the Medical Director of Interventional Pulmonology and Complex Airway Disease Programs at the Inova Health System in Virginia, Dr. Bhatt is the Director of the Center for Lung Analytics and Imaging Research as well as the Medical Director of the Pulmonary Function and Exercise Physiology Lab and the Pulmonary Rehabilitation Program at the University of Alabama at Birmingham, and Dr. Kurman is an Associate Professor of Medicine at the Medical College of Wisconsin and the Director of Interventional Pulmonology at Froedtert and Medical College of Wisconsin Health Network. This program is produced in partnership with the American College of Chest Physicians and is sponsored by Pulmonx, the maker of the Zephyr Valve.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/ Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patient risk factors that impact outcomes. This module covers how pulmonary exacerbations influence disease course and highlights new insights from recent clinical trials. Stay ahead of the curve with updates on emerging therapies that could transform how we manage this challenging disease.=

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/ Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patient risk factors that impact outcomes. This module covers how pulmonary exacerbations influence disease course and highlights new insights from recent clinical trials. Stay ahead of the curve with updates on emerging therapies that could transform how we manage this challenging disease.=

Moderator: Gerard A. Silvestri MD, MS, Master FCCP Guest: Jessica S. Donington, MD, MSCR Guest: Mariam Alexander, MD, PhD Guest: Anurag Singh, MD Recent data from ASCO and ASTRO 2025 are redefining standards of care for resectable non-small cell lung cancer (NSCLC). Drs. Gerard Silvestri, Mariam Alexander, Anurag Singh, and Jessica Donington review these updates on the importance of molecular testing, careful surgical selection, and multidisciplinary planning to optimize personalized treatment pathways. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Alexander is an Assistant Professor of Medical Oncology at the Medical University of South Carolina; Dr. Singh is the Director of Radiation Research, Director of Head and Neck and Lymphoma Radiation Services, and the Associate Dean of Graduate Medical Education in Radiation Medicine at Roswell Park Comprehensive Cancer Center in Buffalo, New York; and Dr. Donington is a Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Moderator: Gerard A. Silvestri MD, MS, Master FCCP Guest: Jessica S. Donington, MD, MSCR Guest: Mariam Alexander, MD, PhD Guest: Anurag Singh, MD Effective care for non-small cell lung cancer (NSCLC) now depends on early molecular testing and coordinated input from a variety of specialties. Dr. Gerard Silvestri sits down with Drs. Jessica Donington, Mariam Alexander, and Anurag Singh to review why multidisciplinary integration is critical to avoid treatment delays, ensure appropriate therapy selection, and ultimately improve patient outcomes. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Donington is a Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago; Dr. Alexander is an Assistant Professor of Medicine and Medical Oncology at the Medical University of South Carolina; and Dr. Singh is the Director of Radiation Research, Director of the Head and Neck and Lymphoma Radiation Services, and the Associate Dean of Graduate Medical Education in Radiation Medicine at Roswell Park Comprehensive Cancer Center in Buffalo, New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Michael Ghobrial, MD Guest: Anju T Peters, MD, MSCI, FAAAAI Guest: Michael S. Blaiss, MD, FACAAI, FAAAAI Refractory chronic cough (RCC) is a debilitating condition that is often misunderstood and underdiagnosed, leaving patients with persistent symptoms despite standard treatment. Hear from Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss as they clarify the definition of RCC, outline essential diagnostic steps, and review current and emerging management strategies. Dr. Ghobrial is the Director of the Chronic Cough Clinic at Cleveland Clinic; Dr. Peters is a Professor of Medicine and Associate Chief of Clinical Research and Practice and Operation in the Division of Allergy and Immunology at Northwestern Medicine; and Dr. Blaiss is a Clinical Professor of Pediatrics at the Medical College of Georgia and an allergist at Good Samaritan Health Center of Gwinnett. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with GSK.

Host: Michael Ghobrial, MD Guest: Anju T Peters, MD, MSCI, FAAAAI Guest: Michael S. Blaiss, MD, FACAAI, FAAAAI Refractory chronic cough can persist for years despite guideline-based therapy, significantly affecting patients' physical, social, and psychological wellbeing. Leading experts Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss explain how to distinguish RCC from other types of chronic cough, outline effective diagnostic strategies, and explore emerging treatment options. Dr. Ghobrial is the Director of the Chronic Cough Clinic at Cleveland Clinic; Dr. Peters is a Professor of Medicine and the Associate Chief of Clinical Research and Practice Innovation in the Division of Allergy and Immunology at Northwestern Medicine; and Dr. Blaiss is a Clinical Professor of Pediatrics at the Medical College of Georgia and an allergist at Good Samaritan Health Center of Gwinnett. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with GSK.

CME credits: 1.00 Valid until: 12-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-care-for-crswnp-expert-and-patient-insights/36695/ Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they: Breakdown how to recognize key inflammatory patterns. Discuss the burden of illness and goals of treatment Interpret clinical trial data on biologic treatments. Apply a collaborative care approach to improve patient outcomes. Watch now to explore cases with patient panelists, expert perspectives, and evidence-based strategies for managing CRSwNP in multidisciplinary settings. =

CME credits: 1.00 Valid until: 12-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-care-for-crswnp-expert-and-patient-insights/36695/ Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they: Breakdown how to recognize key inflammatory patterns. Discuss the burden of illness and goals of treatment Interpret clinical trial data on biologic treatments. Apply a collaborative care approach to improve patient outcomes. Watch now to explore cases with patient panelists, expert perspectives, and evidence-based strategies for managing CRSwNP in multidisciplinary settings. =

Guest: Paola Marignani, PhD, EMBA While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-cell RNA sequencing and machine learning. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Guest: Paola Marignani, PhD, EMBA While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-cell RNA sequencing and machine learning. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.1,2 However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages.3,4 References: King SM, Bryan SP, Hilchey SP, Wang J, Zand MS. First impressions matter: Immune imprinting and antibody cross-reactivity in influenza and SARS-CoV-2. Pathogens. 2023;12(2):169. doi:10.3390/pathogens12020169 Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202(2):335–340. doi:10.4049/jimmunol.1801149 Rockman S, Laurie K, Ong C, et al. Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052 Liu F, Gross FL, Jefferson SN, et al. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J Clin Invest. 2021;131(8):e146138. doi:10.1172/JCI146138 USA-CRP-24-0038 July 2025

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-comparison-of-proms-and-how-to-use-them-in-clinical-practice-for-pah/33241/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-role-in-clinical-research-and-contributions-to-pah-patient-perspectives/33244/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-in-clinical-practice-impacting-treatment-decisions/33243/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-reported-outcome-measures-proms-valuable-insights-into-the-lived-experience-of-pah/33240/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-patient-centered-recommendations-from-the-7th-world-symposium-on-ph/33236/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-travel-with-pah-logistics-medications-oxygen-and-emergency-preparedness/33237/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/aligning-pah-treatment-plans-with-key-care-goals-and-your-patients-priorities/33238/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/what-challenges-and-triumphs-do-patients-face-while-living-with-pah/33242/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-role-in-clinical-research-and-contributions-to-pah-patient-perspectives/33244/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-in-clinical-practice-impacting-treatment-decisions/33243/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/what-challenges-and-triumphs-do-patients-face-while-living-with-pah/33242/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-comparison-of-proms-and-how-to-use-them-in-clinical-practice-for-pah/33241/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-reported-outcome-measures-proms-valuable-insights-into-the-lived-experience-of-pah/33240/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/aligning-pah-treatment-plans-with-key-care-goals-and-your-patients-priorities/33238/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-travel-with-pah-logistics-medications-oxygen-and-emergency-preparedness/33237/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-patient-centered-recommendations-from-the-7th-world-symposium-on-ph/33236/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Learning Objectives:By the end of this series, listeners should be able to discuss:The physiologic rationale supporting the use of airway pressure release ventilation (APRV) in ARDS. The patient populations most likely to benefit from APRV.Key published evidence that informs our use of APRV in critical care.An expert approach to managing a patient with APRV.Next steps in research that will direct our understanding of the use of APRV in pediatric critical care.About our Guest: Dr. Palen Mallory is an assistant professor of pediatrics at Duke University and a pediatric intensivist at Duke Children's Hospital. She completed medical school at Virginia Commonwealth University, a pediatric residency at Emory University, and a critical care fellowship at Vanderbilt University. She is interested in respiratory care research, including ECMO, respiratory failure, and ARDS.Selected References:Mallory, P., & Cheifetz, I. (2020). A comprehensive review of the use and understanding of airway pressure release ventilation. Expert Review of Respiratory Medicine, 14(3), 307–315. https://doi.org/10.1080/17476348.2020.1708719Frawley, P. M., & Habashi, N. M. (2004). Airway pressure release ventilation and pediatrics: Theory and practice. Critical Care Nursing Clinics of North America, 16(3 SPEC. ISS.), 337–348. https://doi.org/10.1016/J.CCELL.2004.04.003Fredericks, A. S., Bunker, M. P., Gliga, L. A., Ebeling, C. G., Ringqvist, J. R. B., Heravi, H., Manley, J., Valladares, J., & Romito, B. T. (2020). Airway Pressure Release Ventilation: A Review of the Evidence, Theoretical Benefits, and Alternative Titration Strategies. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 14. https://doi.org/10.1177/1179548420903297APRV Guideline - EMCrit Project. (n.d.). Retrieved March 30, 2025, from https://emcrit.org/squirt/aprv/Andrews P, Shiber J, Madden M, Nieman GF, Camporota L, Habashi NM. Myths and Misconceptions of Airway Pressure Release Ventilation: Getting Past the Noise and on to the Signal. Front Physiol. 2022 Jul 25;13:928562. doi: 10.3389/fphys.2022.928562. PMID: 35957Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Learning Objectives:By the end of this series, listeners should be able to discuss:The physiologic rationale supporting the use of airway pressure release ventilation (APRV) in ARDS. The patient populations most likely to benefit from APRV.Key published evidence that informs our use of APRV in critical care.An expert approach to managing a patient with APRV.Next steps in research that will direct our understanding of the use of APRV in pediatric critical care.About our Guest: Dr. Palen Mallory is an assistant professor of pediatrics at Duke University and a pediatric intensivist at Duke Children's Hospital. She completed medical school at Virginia Commonwealth University, a pediatric residency at Emory University, and a critical care fellowship at Vanderbilt University. She is interested in respiratory care research, including ECMO, respiratory failure, and ARDS.Selected References:Mallory, P., & Cheifetz, I. (2020). A comprehensive review of the use and understanding of airway pressure release ventilation. Expert Review of Respiratory Medicine, 14(3), 307–315. https://doi.org/10.1080/17476348.2020.1708719Frawley, P. M., & Habashi, N. M. (2004). Airway pressure release ventilation and pediatrics: Theory and practice. Critical Care Nursing Clinics of North America, 16(3 SPEC. ISS.), 337–348. https://doi.org/10.1016/J.CCELL.2004.04.003Fredericks, A. S., Bunker, M. P., Gliga, L. A., Ebeling, C. G., Ringqvist, J. R. B., Heravi, H., Manley, J., Valladares, J., & Romito, B. T. (2020). Airway Pressure Release Ventilation: A Review of the Evidence, Theoretical Benefits, and Alternative Titration Strategies. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 14. https://doi.org/10.1177/1179548420903297APRV Guideline - EMCrit Project. (n.d.). Retrieved March 30, 2025, from https://emcrit.org/squirt/aprv/Andrews P, Shiber J, Madden M, Nieman GF, Camporota L, Habashi NM. Myths and Misconceptions of Airway Pressure Release Ventilation: Getting Past the Noise and on to the Signal. Front Physiol. 2022 Jul 25;13:928562. doi: 10.3389/fphys.2022.928562. PMID: 35957Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.